Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Non-cash Items (2016 - 2025)

Celldex Therapeutics has reported Non-cash Items over the past 14 years, most recently at $5.3 million for Q4 2025.

  • Quarterly results put Non-cash Items at $5.3 million for Q4 2025, up 32.76% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (up 32.76% YoY), and the annual figure for FY2025 was $5.3 million, up 32.76%.
  • Non-cash Items for Q4 2025 was $5.3 million at Celldex Therapeutics, up from $5.1 million in the prior quarter.
  • Over the last five years, Non-cash Items for CLDX hit a ceiling of $93.1 million in Q2 2024 and a floor of $982848.0 in Q1 2021.
  • Median Non-cash Items over the past 5 years was $5.0 million (2025), compared with a mean of $22.4 million.
  • Biggest five-year swings in Non-cash Items: skyrocketed 4282.03% in 2021 and later crashed 94.71% in 2025.
  • Celldex Therapeutics' Non-cash Items stood at $84.7 million in 2021, then plummeted by 49.35% to $42.9 million in 2022, then crashed by 92.4% to $3.3 million in 2023, then rose by 22.03% to $4.0 million in 2024, then skyrocketed by 32.76% to $5.3 million in 2025.
  • The last three reported values for Non-cash Items were $5.3 million (Q4 2025), $5.1 million (Q3 2025), and $4.9 million (Q2 2025) per Business Quant data.